Difficult to recover equity transfer funds. Harbin Gloria Pharmaceuticals' PD-1 "divestiture" lawsuit may face a second instance | Quick Reading of Announcement.
① After winning the first instance, Harbin Gloria Pharmaceuticals has further developments in the lawsuit regarding the separation of Innovative Drugs assets. ② The acquiring party, Puxing Puli, has filed an appeal, requesting a ruling that it is not required to pay any penalties to Harbin Gloria Pharmaceuticals.
To extend its Industry Chain layout, Sansure Biotech Inc. intends to acquire 54% equity in Hong'an Jiyuan, which has not yet turned a profit.
①Sansure Biotech Inc. stated that the company values the product's ease of operation, good stability, and high cost performance of Hong'an Jiyuan, making it suitable for projects in grassroots Medical Institutions; ②Since the launch of related products from Hong'an Jiyuan in 2024, thousands of blood analyzers have been installed in various provinces across the country within one year.
Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.
① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.
A new generic version of enteric-coated esomeprazole has been approved, breaking Livzon Pharmaceutical Group Inc.'s monopoly on this exclusive large product worth "1.3 billion+".
① CSPC PHARMA's Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Aplrazole enteric-coated tablets have recently been approved, breaking Livzon Pharmaceutical Group Inc.'s monopoly in this drug field; ② Industry experts believe that a price war in the Aplrazole enteric-coated tablet market is only possible when the number of approved companies reaches four or more.
Investment in Ultra High Pressure continues to accelerate, and Analysts predict that the bidding process is expected to speed up in 2025.
① The "Xinjiang Power Transmission to Chongqing" project, the Hami-Chongqing ±800 kV Ultra High Pressure Direct Current transmission line project, has been fully connected. ② Xiangcai Securities believes that Ultra High Pressure is a key infrastructure for the delivery of large New energy Fund bases, and 2025 marks the concluding year of the 14th Five-Year Plan. To promote the consumption of New energy Fund, the progress of bidding in 2025 is expected to accelerate.
After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?
① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.